Former Otonomy CSO LeBel Joins Frequency Therapeutics as Executive VP

Xconomy Boston — 

Frequency Therapeutics has appointed Carl LeBel to serve as executive vice president of clinical development of the Woburn, MA, company. LeBel most recently worked for San Diego-based ear medicines company Otonomy, where he was chief scientific officer from 2009 through 2016. Frequency’s lead drug for hearing loss, FX-322, is expected to begin Phase 2 studies in the second half of this year.